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Abstract: High grade serous ovarian cancer (HGSOC) is a major cause of female cancer mortality.
The approval of poly (ADP-ribose) polymerase (PARP) inhibitors for clinical use has greatly improved
treatment options for patients with homologous recombination repair (HRR)-deficient HGSOC,
although the development of PARP inhibitor resistance in some patients is revealing limitations to
outcome. A proportion of patients with HRR-proficient cancers also benefit from PARP inhibitor
therapy. Our aim is to compare mechanisms of resistance to the PARP inhibitor olaparib in these
two main molecular categories of HGSOC and investigate a way to overcome resistance that we
considered particularly suited to a cancer like HGSOC, where there is a very high incidence of TP53
gene mutation, making HGSOC cells heavily reliant on the G2 checkpoint for repair of DNA damage
and survival. We identified alterations in multiple factors involved in resistance to PARP inhibition
in both HRR-proficient and -deficient cancers. The most frequent change was a major reduction in
levels of poly (ADP-ribose) glycohydrolase (PARG), which would be expected to preserve a residual
PARP1-initiated DNA damage response to DNA single-strand breaks. Other changes seen would
be expected to boost levels of HRR of DNA double-strand breaks. Growth of all olaparib-resistant
clones isolated could be controlled by WEE1 kinase inhibitor AZD1775, which inactivates the G2
checkpoint. Our work suggests that use of the WEE1 kinase inhibitor could be a realistic therapeutic
option for patients that develop resistance to olaparib.
Keywords: PARP inhibitor; olaparib; resistance mechanism; DNA repair; WEE1 kinase; ovarian cancer
1. Introduction
Ovarian cancer is the eighth most common female cancer and the eighth most common cause of
female cancer death worldwide (GLOBOCAN 2018 estimates, [1]). High grade serous ovarian
cancer (HGSOC) comprises 75–80% of ovarian cancers and is characterized by TP53 mutation
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and genetic heterogeneity [2]. The two major molecular categories are homologous recombination
repair (HRR)-proficient and HRR-deficient, which is often due to the loss of function of the BRCA1 or
BRCA2 genes [3]. Most HGSOC cases are treated with combined surgery and chemotherapy based
on carboplatin and a taxane [4]. Although patients with HRR-deficient cancers initially respond well,
the majority relapse after first line chemotherapy.
Poly (ADP-ribose) polymerase 1 (PARP1) is essential for the repair of DNA single-strand breaks
(SSBs) [5]. PARP inhibitors (PARPi), such as olaparib, block the catalytic site on PARP1 and trap
the enzyme on the DNA while preventing catalytic activity [6]. The structural basis for the ability
of PARPi to trap PARP1 on the DNA has recently been determined [7]. Unrepaired SSBs with
trapped PARP1 that persist into replication are believed to lead to the collapse of replication forks [8].
The resulting DNA double-strand breaks (DSBs) are preferentially and accurately repaired by HRR.
In BRCA-deficient tumors, the HRR pathway is not functional and repair is directed instead toward
the error-prone non-homologous end joining (NHEJ) pathway, resulting in large-scale genome
instability and cell death. Thus, PARP inhibition is synthetically lethal in HRR-deficient HGSOC, with
BRCA-deficient cells displaying ~1000-times greater sensitivity to PARP inhibitors than wild-type
cells [9,10]. Clinical response to PARP inhibitor olaparib was first demonstrated in germline BRCA
mutation carriers in phase 1 trials [11,12]. A phase 2 study reported that PARP inhibitors might
be an alternative to conventional chemotherapy, with a more favorable toxicity profile, in a patient
population with relapsed disease and BRCA mutation [13]. Another phase 2 study, in the relapsed
HGSOC maintenance setting, showed prolonged progression-free survival (PFS) of 8.4 months in
the olaparib arm, vs. 4.8 months in the placebo arm [14]. Recently, a landmark phase 3 trial (SOLO1)
found that use of olaparib as first-line maintenance therapy provided a significant PFS benefit (risk of
disease progression and death was 70% lower with olaparib than with placebo) among women with
newly diagnosed advanced ovarian cancer and a BRCA mutation [15].
There is growing evidence that olaparib [16] and other PARPi may also be effective in the treatment
of HGSOCs without clearly identifiable defects in the HRR pathway. A phase 3 trial of niraparib
maintenance therapy in platinum-sensitive, recurrent HGSOC reported a > 3-fold increase in PFS over
placebo for patients who had either germline BRCA mutations, or another cause of HRR deficiency.
Niraparib also improved PFS for patients in the HRR-proficient subgroup [17]. A similar result
was obtained in a phase 3 trial for another PARPi, rucaparib, being used in maintenance treatment
for recurrent ovarian carcinoma. Rucaparib also improved PFS for patients in the HRR-proficient
subgroup [18]. Recent analysis of tumour samples from an olaparib maintenance monotherapy phase
2 trial for platinum-sensitive, recurrent HGSOC (Study 19) has also reported an increase in PFS for
the HRR-proficient subgroup [19]. In each of these three studies HRR-proficiency was defined as
no BRCA mutations and no evidence of an HRR deficit in a next generation sequencing-based assay.
The molecular basis for this unanticipated benefit in HRR-proficient HGSOC could be the ability of
PARPi to trap PARP1 on replicating DNA, but PARP1 is also reported to be able to protect HRR from
interference by proteins involved in NHEJ [20].
While PARP inhibitors have greatly improved treatment options for HRR-deficient HGSOC,
development of PARP inhibitor resistance in some patients limits the clinical outcome [21].
In vitro and in vivo models suggest that PARPi resistance can occur by a variety of independent
mechanisms [22–36]. The aim of this study is to compare mechanisms of resistance to PARP inhibitor
olaparib in HRR-proficient and -deficient HGSOC cells and then use the resistant cells to test a method
to overcome olaparib resistance considered particularly appropriate for HGSOC. Near universal
TP53 mutation in HGSOCs [3] inactivates the G1 checkpoint making them heavily reliant on the G2
checkpoint for DNA damage repair and survival. This checkpoint is controlled by the phosphorylation
status of CDK1. WEE1 kinase responds to DNA damage with inhibitory phosphorylation of CDK1,
causing G2 arrest and so giving time for DNA repair before entering into mitosis [37]. For this reason,
we sought to test whether HGSOC cells with acquired resistance to olaparib could effectively respond
to treatments with the WEE1 inhibitor AZD1775 [38].
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2. Results
2.1. Generation of Olaparib-Resistant HGSOC Clones
From our panel of validated HGSOC cell lines [39,40], ES-2 (HRR-proficient) and OVCAR8
(HRR-deficient due to hypermethylation of the BRCA1 gene promoter [41]) were chosen for
the isolation of olaparib-resistant clones because of their good colony forming ability when seeded
thinly. Independent olaparib-resistant ES-2 and OVCAR8 clones were isolated by thinly plating cells
(1000 and 1500 cells per well) in a 96-well plate and treating with 25 or 50 µM olaparib for ES-2
and 12 µM olaparib for OVCAR8. These selective concentrations of olaparib were chosen based on
the results of growth assays described in the next paragraph. Colonies became visible after four weeks
and arose at a frequency of 8 × 10−5 for ES-2 and 5 × 10−5 for OVCAR8. Only wells containing single
colonies were used to isolate resistant clones, which were expanded and maintained under continuous
selection. Six clones resistant to 25 µM and two clones resistant to 50 µM olaparib were isolated from
ES-2, while nine clones resistant to 12 µM olaparib were isolated from OVCAR8. Resistant clones
used for further analysis are shown in Figure 1. The nomenclature system used for resistant clones
was chosen to indicate the cell line used, selective agent, its concentration, and an identifying number.
Thus, ES-2 OLA_50:1 is ES-2 clone number 1, selected for resistance to 50 µM olaparib.
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a IC50 for olaparib of 25 µM in the five-day SRB growth assay, while the HRR-d fici nt and so more
sensitive OVCAR8 line had a 10-fold lower olaparib IC50 of 2 µM in the same assay (Figur 2A,B).
All the four OVCAR8 clones assayed (IC50s ranging from 50–65 µM) showed > 25-fold increases in
IC50 values compared to the OVCAR8 parent (IC50 2 µM; Figure 2B). Apparent levels of resistance
in this assay were much less for the four ES-2 clones (IC50s ranging from 30–65 µM) compared to
the ES-2 parent (IC50 25 µM): 2–3-fold higher for the 50 µM clones, and taking the 95% confidence
intervals into account, at best only marginal increases for 25 µM clones (Figure 2A). Reasoning that
the tandard five-day growth assay was t o short to reveal the true difference in olaparib r sistance
between our ES-2 clones a d the ES-2 par nt, because the ph otypic effects of PARPi require > 5
population doubling times for accurate measurement [43,44], we instead used an eleven-d y survival
assay (Figure 2C). In this survival assay the IC50 for the ES-2 parent (4 µM) was much lower than in
the s orter growth assay (25 µM), while the IC50s for the resistant clones were essentially u affected.
The two clones r sistant to 25 µM lapa ib now showed ~10-fold increased IC50 values compared to
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the ES-2 parent, while the IC50 value for ES-2 OLA_50:1 was 20-fold higher, confirming the improved
accuracy of a long term proliferation assay for the evaluation of PARPi.
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Figure 2. Decreased sensitivity of olaparib-resistant clones to olaparib. (A) Five-day growth assay for
four ES-2 clones resistant to 25 or 50 µM olaparib. ES-2 parent is shown in red, 25 µM clones are in
green, and 50 µM clones are in blue. IC50 values for each cell line (µM ± SEM) are shown in parentheses.
95% confidence intervals for IC50 values are shown as colored vertical bars. (B) Five-day growth assay
for four OVCAR8 clones resistant to 12 µM olaparib. OVCAR8 parent is shown in blue, resistant clones
are in pink. IC50 values (µM ± SEM) are shown in parentheses. (C) Eleven-day survival assay for three
of the ES-2 clones shown in the growth assay above. ES-2 parent in red, 25 µM clones in green, 50 µM
clone in blue. IC50 values (µM) are shown in parentheses.
2.2. Changes Associated with Olaparib Resistance in HGSOC Clones
To investigate the mechanism of olaparib resistance in our HRR-proficient and -deficient HGSOC
clones, protein lysates were Western blotted for proteins previously found to be involved in PARPi
resistance mechanisms in HRR-deficient cells [22–36]. Lysates were made from resistant clones grown
under olaparib selection, while parental cell lysates were made from cells in ordinary medium. Blots for
ES-2 and three resistant ES-2-derived clones are shown in Figure 3A and histograms showing the relative
expression of the proteins in resistant clones, compared to the ES-2 parent, are shown in Figure 3B. PARP1
in the ES-2 parent showed a low level of self poly (ADP-ribosylation) [auto-PARylation]. Although
PARP1 levels were unaltered in resistant clones, the ability of olaparib to block PARP1 auto-PARylation
in the resistant clones, which were maintained under selection, was clearly shown. Some increment
in levels of γH2AX, the chromatin marker for DSBs [45], was seen in all olaparib-resistant clones,
most likely as a consequence of the olaparib treatment. There was no evidence for upregulation of
the MDR1 membrane glycoprotein efflux pump being involved in resistance. The most noticeable
change among proteins analyzed here, that are known to be involved in olaparib resistance, was
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the major reduction (> 5-fold) in levels of PARG (PAR glycohydrolase) in all the resistant clones. While
REV7 levels were unaffected in resistant clones, all clones analyzed showed reduced levels of RIF1
(with a major reduction in clone ES-2 OLA_50:1) and 53BP1 (with a major reduction in clone ES-2
OLA_25:6). Although one of the two 25 µM clones (ES-2 OLA_25:5) showed a decreased level of EZH2
and H3K27Me3, levels of MUS81 endonuclease were largely unaffected in all clones.
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green. ES-2 OLA_50:1, shown in blue, is resistant to 50 µM AZD1775. Note that the apparent reduction
in levels of BRCA1 in clone ES-2 OLA_50:1 most likely reflects a problem with the transfer. Information
supporting the identification of proteins in these western blots is shown in Figure S1.
Four OVCAR8-derived clones were also tested for changes in protein expression relevant to
olaparib resistance (Figure 4). As with ES-2 clones, PARP1 levels were unaltered in OVCAR8-resistant
clones and the ability of olaparib to block auto-PARylation of PARP1 was again evident in clones
maintained in olaparib. Compared to ES-2 clones, there was consistently greater elevation of the γH2AX
DNA damage marker. Again, as in ES-2, there was no evidence that increased levels of MDR1 were
involved in resistance. The low level of BRCA1 protein observed in the OVCAR8 parent was expected,
given that methylation of the BRCA1 gene promoter has been reported in this cell line [41]. All
resistant OVCAR8 clones showed upregulation of BRCA1 protein levels, with the largest increase in
OVCAR8 OLA_12:3. Two of the clones with the smallest increase in BRCA1 protein (OVCAR8 OLA_12:4
and OVCAR8 OLA_12:5) also showed major reductions (> 10-fold) in PARG levels. The same two clones
also showed equivalent large reductions in levels of RIF1 and modest reduction in 53BP1, while REV7
levels were unaffected. Clone OVCAR8 OLA_12:1 also showed a modest reduction in levels of RIF1.
No changes previously associated with olaparib resistance were seen in the EZH2/H3K27Me3/MUS81
replication fork stabilization pathway. The elevated level of H3K27Me3 in clones OVCAR8 OLA_12:1
and OVCAR8 OLA_12:3 is the opposite of the change in this histone mark that has been associated
with olaparib resistance and its significance is unclear.
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under olaparib selection. (A) Western blots for 53BP1, BRCA1, RIF1, PARP1, PARG, MDR1, MUS81,
REV7, EZH2, H3K27Me3, γH2AX from OVCAR8 and four olaparib-resistant OVCAR8 derived clones,
with GAPDH as loading control. (B) Histograms showing levels of the different proteins in each clone,
corrected for differences in loading control, and expressed relative to the level in the OVCAR8 parent.
OVCAR8 parent shown in blue. OVCAR8 clones OVCAR8 OLA_12:1, OVCAR8 OLA_12:3, OVCAR8
OLA_12:4, and OVCAR8 OLA_12:5, resistant to 12.5 µM olaparib, are shown in dark pink. Information
supporting the identification of proteins in these Western blots is shown in Figure S1.
Thus, different protein changes previously reported to cause PARPi resistance were seen in ES-2
and OVCAR8 clones, with examples in both cell types of multiple changes in the same clone.
2.3. Olaparib-Resistant HGSOC Clones Remain Sensitive to WEE1 Inhibition
The very high frequency of TP53 mutation in HGSOC makes this cancer heavily dependent on
the G2 checkpoint, controlled by WEE1 kinase, for cell cycle arrest and DNA damage repair. We next
investigated whether the growth of our olaparib-resistant ES-2 and OVCAR8 clones could be controlled
by WEE1 kinase inhibitor AZD1775 in our five-day SRB growth assay (Figure 5). Of the three ES-2
clones tested, only ES-2 OLA_50:1 showed a small increase (< 2-fold) in AZD1775 IC50 value compared
to ES-2 (Figure 5A). While all four OVCAR8 clones had the same sensitivity to AZD1775 as the parent
OVCAR8 cell line (Figure 5B). We conclude that clones from these two HGSOC cell lines that display
resistance to olaparib remain as sensitive to AZD1775 as their parental cell lines.
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Figure 5. Sensitivity of olaparib-resistant HGSOC clones to WEE1 inhibition. (A) Olaparib resistant
ES-2 clones remain largely sensitive to AZD1775. AZD1775 growth curves for three independent ES-2
clones resistant to 25 µM (green) or 50 µM olaparib (blue) are shown. ES-2 parent curve is in red.
AZD1775 IC50 values for each curve (in nM ± SEM) are shown in brackets. 95% confidence intervals
for IC50 values are shown as colored vertical bars. (B) Olaparib resistant OVCAR8 clones remain
sensitive to AZD1775. AZD1775 growth curves for four OVCAR8 clones resistant to 12 µM olaparib
(pink) are shown. OVCAR8 parent curve is in blue. AZD1775 IC50 values for each curve (in nM ±
SEM) are shown in brackets. All olaparib-resistant clones show the same sensitivity to AZD1775 as
the OVCAR8 parent.
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3. Discussion
The detection of SSBs by PARP1 triggers a DNA damage response (DDR) leading to their repair [46].
PARP inhibition is particularly effective in one of the two major molecular categories of HGSOC, where
the HRR pathway for DSBs is defective [11–15]. As a consequence of PARP inhibition and PARP1
trapping on the DNA, SSBs persist into replication resulting in their conversion to DSBs. The ability of
PARPi to trap PARP1 on replicating DNA [6] and a report that PARP1 can protect HRR from interference
by proteins involved in NHEJ [20], raise the possibility that it could also be effective in some cases
of HRR-proficient HGSOC. This suggestion has been supported by analysis of three recent trials of
maintenance therapy with PARP inhibitors olaparib, niraparib, and rucaparib in platinum-sensitive,
recurrent HGSOC. In addition to major survival benefits in HRR-deficient patients, there were also
increases in PFS for patients in the HRR-proficient subgroups [17–19].
To further explore this preclinically, we chose to isolate olaparib-resistant clones from both
HRR-deficient (OVCAR8) and HRR-proficient (ES-2) HGSOC cell lines, so that we could investigate
resistance mechanisms and test ways to overcome olaparib resistance, particularly by exploiting
the TP53 gene deficiency found in HGSOC.
A previous study of patient-derived HGSOC xenografts found that methylation of all BRCA1 gene
copies, leading to silencing of the gene, predicted sensitivity to PARPi, while heterozygous methylation
was associated with resistance [47]. In the HRR-proficient ES-2 cell line, the IC50 for olaparib in a 5-day
growth assay was > 10-fold higher than in OVCAR8, where methylation of the BRCA1 gene promoter
has been reported [41] and is the likely cause of the HRR-deficiency [48] and resulting sensitivity
to olaparib and other PARPi. Olaparib-resistant OVCAR8 clones had > 25-fold higher IC50s than
the OVCAR8 parent in the 5-day growth assay, whereas olaparib-resistant ES-2 clones showed a much
smaller IC50 increase (< 3-fold) over the ES-2 parent (IC50 25 µM) in the same assay. When an 11-day
survival assay was used instead, to give the longer time needed for PARP inhibitor-treated cells with
an intact HRR pathway to go through enough cell doublings to accumulate sufficient DNA damage
to result in cell death [43,44], the difference between the ES-2 parent (IC50 now reduced to 4 µM)
and resistant clones became much more apparent, with IC50s up to 20-fold higher than the parent.
Multiple mechanisms of PARPi resistance have been described, mostly in HRR-deficient breast
cancer or HGSOC cells with BRCA mutations. Changes that preserve the DNA damage response (DDR)
triggered by the action of PARP1 at SSBs, such as altered expression or mutation of PARP1 [22], or
downregulation of the enzyme PARG (poly [ADP-ribose] glycohydrolase), that removes PARP-catalyzed
poly (ADP-ribosylation) [PARylation], can both result in resistance [23]. Restoration of HRR function
by secondary BRCA mutation [24,25] is the only clinically confirmed resistance mechanism reported so
far. Translation initiation downstream of a frameshift mutation [26], or stabilization of mutant BRCA
proteins [27], can also lead to resistance. Enhanced drug efflux, resulting from increased expression
of the MDR1/PgP (multidrug resistance protein 1/P-glycoprotein) membrane transporter protein,
was also linked to acquired resistance in preclinical models [28,29]. Reduced expression of 53BP1
(p53 binding protein 1) in BRCA1-deficient cells, or of members of its effector complex, such as RIF1
and REV7, which normally act to prevent DSBs from undergoing BRCA1-mediated end processing
and instead direct repair down the error-prone NHEJ pathway, can boost HRR activity resulting
in PARPi resistance [30–33]. Stabilization of stalled DNA replication forks by inhibition of MRE11
nuclease in BRCA-deficient cells can also lead to PARPi resistance [34]. Localization of the EZH2
protein at stalled replication forks trimethylates Lys27 on Histone H3 and so recruits MUS81 nuclease
to degrade the fork. Low EZH2 levels prevent MUS81 recruitment and so stabilize the fork, resulting
in resistance to PARPi [35]. Activation of epithelial-mesenchymal transition in a mouse model of
BRCA2-deficient breast cancer has also been found to trigger olaparib resistance [36].
Here we have investigated mechanisms of olaparib resistance in HRR-deficient and -proficient
HGSOC cells. We chose to use OVCAR8, with methylation of the BRCA1 gene promoter as our
HRR-deficient and platinum-sensitive cell line, rather than a BRCA mutant line from our HGSOC cell
line panel, because of its superior ability to plate at the low cell densities required to isolate individual
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resistant clones. A major reduction in levels of PARG protein was found in all olaparib-resistant clones
isolated from HRR-proficient ES-2 cells. The reduction was greatest in ES-2 OLA_50:1, the clone with
the highest IC50 for olaparib in our survival assay. PARG degrades the PAR chains that are added
by PARP1 at sites of SSBs and which are reported to be essential for DNA repair protein recruitment
and processing of DNA damage. This reduction in PARG would be expected to preserve any residual
PARylation carried out by PARP1 in the presence of olaparib and so rescue some downstream PARP
signaling and repair of SSBs [23]. Reductions in the level of 53BP1 (especially in ES-2 OLA_25:6) and of
RIF1 (especially in ES-2 OLA_50:1) in resistant ES-2 clones would direct repair of DSBs away from
the error-prone NHEJ pathway and instead down the HRR pathway to lead to cell survival [30–33].
Levels of MUS81 were also lowest in ES-2 OLA_50:1, which could also aid olaparib survival by
preserving the stability of stalled replication forks [35]. Unsurprisingly, more changes appeared to
be necessary to achieve olaparib resistance in individual clones in the HRR-deficient OVCAR8 cells.
Increased levels of BRCA1 were seen in all resistant clones which would be expected to boost HRR,
with highest levels in OVCAR8 OLA_12:3. Major reductions in PARG and RIF1 and reduced levels of
53BP1 were also seen in OVCAR8 OLA_12:4 and OVCAR8 OLA_12:5, while the clones with the highest
levels of BRCA1, OVCAR8 OLA_12:1, and OVCAR8 OLA_12:3, had smaller reductions in PARG, no
reduction of 53BP1 and only OVCAR8 OLA_12:1 had reduced RIF1. There was no evidence in either
cell line for a role in resistance of increased expression of the MDR1/PgP membrane transporter protein,
which has been reported as a frequent cause of resistance to PARP inhibition in other studies in breast
and ovarian cancer cells [28,29].
In these two different HGSOC cell models, we have observed several previously described olaparib
resistance mechanisms. Independent of HRR status, PARG downregulation to preserve the DDR to
SSBs was observed in most clones. A variety of different ways to boost HRR of DSBs were also observed,
notably increased levels of BRCA1 protein and downregulation of 53BP1 and RIF1. No information
was obtained during the study to explain the basis for these altered protein levels. Several of these
resistance mechanisms co-existed in the same resistant cell clone, suggesting that in some cases a single
mechanism may be insufficient for cells to overcome the actions of olaparib. As far as we are aware
this is the first time that these mechanisms have been reported to occur together in the same resistant
clone. Although functional studies would be needed to investigate this further, this result could be
very relevant for olaparib resistance in the clinic, where it would suggest that more than one resistance
mechanism may need to be addressed in the same tumour.
The ES-2 cell line is homologous recombination repair (HRR) proficient and so is naturally less
sensitive to olaparib than the other ovarian cancer cell line used, OVCAR8, which is HRR-deficient (IC50
in our growth assay: ES-2, 25 µM; OVCAR8, 2 µM). We chose to isolate and analyze olaparib-resistant
clones from both HRR-deficient and -proficient cell lines because of recent studies showing that patients
with each molecular subtype of ovarian cancer can benefit from PARP inhibitor therapy [17–19].
The high concentrations of olaparib needed to isolate resistant clones from ES-2 cells could potentially
impact other cell pathways. However, our observation that similar changes associated with olaparib
resistance were seen in resistant clones from both cell types suggests that this is not the case.
With the increasing use of PARPi maintenance therapy for HGSOC patients with HRR-deficiency
and now also for HRR-proficient HGSOC as well, the inevitable development of resistance will pose
a major challenge, necessitating the use of an alternative therapeutic strategy to control tumour growth.
AZD1775 (formerly known as MK-1775) was the first reported WEE1 kinase inhibitor [49]. It is a highly
selective, potent, ATP-competitive, small molecule inhibitor of the kinase domain with an enzyme
IC50 of 5.2 nM in a cell-free assay. Small cell lung cancer patient-derived circulating tumour cell
explant models with HRR-deficiency were found to respond well to olaparib in combination with
WEE1 inhibitor AZD1775 [50]. The very high frequency of TP53 mutation in HGSOC [2] makes this
cancer heavily dependent on the G2 checkpoint that is controlled by WEE1 kinase for cell cycle arrest
and DNA damage repair. Simultaneous treatment of ovarian cancer xenograft models with PARP
and WEE1 inhibition was effective but poorly tolerated, while sequential administration retained
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efficacy with reduced toxicity [51]. In this study we found that olaparib-resistant ES-2 and OVCAR8
clones remained sensitive to AZD1775, suggesting that use of WEE1 kinase inhibition for patients
developing resistance to olaparib could also be a realistic therapeutic option.
4. Materials and Methods
4.1. Mammalian Cell Culture Assays
Human HGSOC cell lines ES-2 and OVCAR8 were obtained from the American Type Culture
Collection, where they were authenticated by short tandem repeat profiling. Both cell lines are TP53
deficient: the HRR-proficient ES-2 cell line has a TP53 missense mutation (S241F, rs28934573), while
the HRR-deficient and platinum-sensitive OVCAR8 cell line has a pathogenic TP53 splice site SNP
and also methylation of the BRCA1 gene promoter [52]. All experiments with these cells were carried
out within 10 passages of supply. Cells were cultured in DMEM (ES-2; #41965, Thermo Fisher Scientific,
Paisley, UK), or RPMI-1640 medium (OVCAR8; #21875, Thermo Fisher Scientific), supplemented with
10% FCS, non-essential amino acids (#11140-035, Thermo Fisher Scientific), 1 mM sodium pyruvate,
2 mM L-glutamine, 0.01 mg/mL insulin and penicillin (100 U/mL)—streptomycin (100 mg/mL) at 37 ◦C,
5% CO2.
To isolate clones resistant to olaparib (S1060, Selleckchem, Houston, TX, USA), cells were plated
at 1000 and 1500 cells/well in 96-well plates in medium containing the selective olaparib concentration
(25 or 50 µM for ES-2 and 12 µM for OVCAR8, determined from the results of 5-day growth assays).
Selection for olaparib resistance was carried out in 96-well plates. To ensure that our analysis was
carried out on single olaparib-resistant clones, rather than clonal mixtures, the plating density was
adjusted so that the average number of resistant colonies arising/well was < 1. Wells were examined
microscopically and colonies were only trypsinized from wells that clearly contained just a single
colony. Colonies typically went through just four passages under continuous olaparib selection (24-well
plate, 6-well plate, 25 cm2 flask, 25 cm2 flasks) before sufficient cells were available to make protein
lysates for analysis.
Sensitivity of cell lines to olaparib, or WEE1 inhibitor AZD1775 (S1525, Selleckchem), was
determined by a five-day Sulphorhodamine B (SRB) growth assay [41]. Cells were plated at 2000 cells
per well into 96-well plates containing an olaparib or AZD1775 dilution series (8 wells for each drug
concentration). Dose response curves and IC50 values, with 95% confidence intervals, were obtained
with GraphPad Prism (San Diego, CA, USA) using a non-linear regression curve fit model.
A clonogenic survival assay was also used on olaparib-resistant ES-2 clones. Cells were plated
at 100,000 cells per well in 6-well plates in medium containing an olaparib dilution series and left for
11 days to allow surviving cells to form colonies. Plates were then fixed, stained, and processed in
the same way as for the SRB growth assay.
4.2. Western Blotting
Protein extraction was carried out on ice using RIPA buffer (25 mM Tris-HCl pH 7.2, 150 mM
NaCl, 1% Triton X-100, 1% deoxycholate, 1 mM EDTA, 20 mM NaF, 100 µM orthovanadate), with
Halt protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific, #78430). Proteins were
quantified with BCA protein assay kit (Thermo Fisher Scientific, #23225). Total of 50 µg of protein
lysates were loaded in each lane of NuPAGE Novex 4–12% bis-tris midi protein gels (Thermo Fisher
Scientific, #WG1402A) and proteins were transferred onto nitrocellulose membrane using the iBlot®
2 Dry Blotting System (Thermo Fisher Scientific). Membranes were cut, blocked in TBS-Tween +
5% milk, and then incubated overnight at 4 ◦C with the primary antibodies as listed in Table S1.
After washes in TBS-Tween, membranes were incubated with the respective secondary antibodies:
HRP-conjugated, anti-mouse (#7076S, Cell Signaling Technology, Danvers, MA, USA), or anti-rabbit
(#7074S, Cell Signaling Technology). Membrane chemiluminescence was developed with Pierce West
Dura substrate (Thermo Fisher Scientific, #34080) and acquired using GBOX (Syngene, Cambridge, UK).
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Protein band quantification was performed with ImageJ and normalized on the GAPDH signal used as
loading control.
5. Conclusions
We have identified multiple changes involved in resistance to PARP inhibition in homologous
recombination repair (HRR)-deficient and also in HRR-proficient high-grade serous ovarian cancer
(HGSOC) cells. The most frequent change, involving major reduction in levels of poly (ADP-ribose)
glycohydrolase, would be expected to preserve a residual DNA damage response initiated by PARP1
in response to DNA single-strand breaks. Other changes seen would be expected to boost levels of
HRR of DNA double-strand breaks. Different resistance mechanisms co-existed in the same resistant
cell clone, suggesting that, in some circumstances, a single mechanism may be insufficient for cells to
overcome the actions of olaparib. As far as we are aware, this is the first time that these mechanisms
have been reported to occur together in the same resistant clone. In a strategy that exploits the TP53
deficiency found in HGSOC, growth of all olaparib-resistant clones could be controlled by WEE1
kinase inhibitor AZD1775.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/6/1503/s1,
Figure S1: Information in support of Western blots shown in Figures 3 and 4, Table S1: Antibodies used for
Western blots.
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